A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...
According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in ...
In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...
Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...
New research reports the creation of a degradation-based cancer vaccine that penetrates tumor cells and converts them into ...
Vaxiion Therapeutics Announces Completion of Phase 1a Dose Escalation and Initiation of a Phase 1b Dose Expansion Study for Intralesional Administration of VAX014 in Combination with PD-1 Directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback